Podcast Atlas
Source note Episode guide Original audio Topics: Economics

vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位

Summary

This 起朱楼宴宾客 episode has 大卫翁 interview 小P老师, an early-research scientist at a Chinese innovation-drug company, about the 2024 biopharma year and a source-dated 2025 outlook. The episode’s central frame is that 2024 produced few pure platform miracles, while asset transactions, China biotech asset repricing, license-out, and reverse NewCo structures became more important. It connects PD-1 saturation, mRNA uncertainty, CAR-T limits, PD-1/VEGF bispecifics, TCEs, ADC engineering, GLP-1 competition, long-acting HIV prevention, Chinese biotech globalization, and AI drug clinical validation into one industry map.

Key Claims

  • 小P老师 keeps the broad view that PD-1, mRNA, and CAR-T are now more realistic than miraculous: PD-1 is crowded, post-COVID mRNA still needs stronger non-vaccine applications, and CAR-T remains difficult in solid tumors and allogeneic versions.
  • The episode treats 2024 as a year of limited technical breakthrough but active transactions, with multinational pharma companies using M&A, BD, and licensing to buy Chinese pipelines at lower relative valuations.
  • China Biotech Asset Repricing is tied to China-U.S. asset price gaps: the same or similar assets can be valued much higher after being moved, licensed, or packaged for the U.S. market.
  • Biotech License-Out Arbitrage remains a major business route, but the episode is more cautious than a simple “license-out equals success” narrative because it can cap upside, affect IPO probability, and complicate fund and tax incentives.
  • Reverse NewCo Biotech Model is presented as a newer pattern in which Chinese pipelines are taken into overseas NewCos, reversing an earlier pattern of importing U.S. assets into China.
  • Multinational Pharma Patent-Cliff Anxiety drives defensive buying: companies such as 默沙东 face pressure to replace future revenue as K药 approaches patent expiration.
  • 康方生物’s PD-1/VEGF bispecific data becomes the episode’s core example of a Chinese asset that can force big pharma to watch closely even while publicly asking for longer survival data.
  • T-cell engagers are framed as cheaper and weaker than CAR-T, but commercially interesting because they may extend immune-cell targeting logic into autoimmune disease markets.
  • ADC Engineering Optimization is treated as an area where Chinese companies may have engineering advantages, because antibody, payload, and linker combinations create many optimization paths.
  • Dual-payload ADCs are presented as a possible later BD wave if clinical or preclinical data justify the added manufacturing and quality-control burden.
  • GLP-1 Agonists are moving into a more crowded consumer-facing market, where efficacy, side effects, approval timing, marketing, celebrity effects, and muscle-preservation claims may all matter.
  • Gilead is split into a strong antiviral/HIV story and a weaker oncology investment story, including setbacks around CD47, TIGIT, and ADC bets in the source’s account.
  • 百济神州 is the episode’s leading Chinese company case because it represents a harder route than ordinary licensing: building global commercial capability around strong products.
  • AI Clinical Validation In Drug Discovery is the 2025 watch item: AI can help molecular design, large-molecule sequence optimization, and target selection, but the episode argues that clinical data ultimately judge the platform story.
  • In vivo mRNA CAR-T is treated as a combination-innovation direction: mRNA-LNP delivery could modify T cells inside the body, but short expression duration may make autoimmune disease more plausible than durable oncology use in the near term.

Key Quotes

“PD-1之后再无奇迹” - the episode’s shorthand for a more sober post-platform-breakthrough mood.

“研发焦虑” - the recurring explanation for why large pharma companies may move quickly even after publicly cautious comments.

“从无限游戏到有限游戏” - the host’s frame for moving from pure breakthrough expectation to competition inside existing drug and asset markets.

Connections

Contradictions